[go: up one dir, main page]

PE20070083A1 - (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona - Google Patents

(5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona

Info

Publication number
PE20070083A1
PE20070083A1 PE2006000617A PE2006000617A PE20070083A1 PE 20070083 A1 PE20070083 A1 PE 20070083A1 PE 2006000617 A PE2006000617 A PE 2006000617A PE 2006000617 A PE2006000617 A PE 2006000617A PE 20070083 A1 PE20070083 A1 PE 20070083A1
Authority
PE
Peru
Prior art keywords
thiazol
dichlorophenyl
amino
methylidene
quinoxalinyl
Prior art date
Application number
PE2006000617A
Other languages
English (en)
Inventor
Kevin J Duffy
Duke M Fitch
Beth A Norton
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20070083A1 publication Critical patent/PE20070083A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO (5Z)-5-(6-QUINOXALINILMETILIDENO)-2- (2,6-DICLOROFENIL)AMINO -1,3-TIAZOL-4(5H)-ONA, Y/O SUS SALES, HIDRATOS, SOLVATOS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHO COMPUESTO ES INHIBIDOR DE LA PROTEINA hYAK3 Y ES UTIL PARA TRATAR O PREVENIR DEFICIENCIAS EN CELULAS ERITROIDES Y HEMATOPOYETICAS TALES COMO ANEMIA, ANEMIA APLASICA, MIELOSUPRESION, CITOPENIA, ENTRE OTRAS
PE2006000617A 2005-06-08 2006-06-06 (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona PE20070083A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68867105P 2005-06-08 2005-06-08

Publications (1)

Publication Number Publication Date
PE20070083A1 true PE20070083A1 (es) 2007-01-27

Family

ID=37532819

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000617A PE20070083A1 (es) 2005-06-08 2006-06-06 (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona

Country Status (21)

Country Link
US (1) US7674792B2 (es)
EP (1) EP1888531A4 (es)
JP (1) JP2008543770A (es)
KR (1) KR20080014017A (es)
CN (1) CN101193863A (es)
AP (1) AP2007004241A0 (es)
AR (1) AR054059A1 (es)
AU (1) AU2006258032A1 (es)
BR (1) BRPI0611096A2 (es)
CA (1) CA2611480A1 (es)
EA (1) EA200702457A1 (es)
IL (1) IL187423A0 (es)
MA (1) MA29567B1 (es)
MX (1) MX2007015572A (es)
NO (1) NO20080130L (es)
NZ (1) NZ563421A (es)
PE (1) PE20070083A1 (es)
TW (1) TW200716580A (es)
UY (1) UY29581A1 (es)
WO (1) WO2006135712A2 (es)
ZA (1) ZA200709813B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543769A (ja) * 2005-06-08 2008-12-04 スミスクライン・ビーチャム・コーポレイション （５ｚ）−５−（６−キノキサリニルメチリデン）−２−［（２，４，６−トリクロロフェニル）アミノ］−１，３−チアゾール−４（５ｈ）−オン
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
US20100184774A1 (en) * 2007-06-01 2010-07-22 Duffy Kevin J Methods of treatment

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5545648A (en) 1978-09-29 1980-03-31 Teikoku Hormone Mfg Co Ltd 2-formyldibenzazepin derivative and its preparation
US5089516A (en) * 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5202341A (en) * 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
US4971996A (en) * 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
JPH0197926A (ja) 1987-10-09 1989-04-17 Idemitsu Kosan Co Ltd 有機非線型光学材料
DD270072A1 (de) 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US5145753A (en) * 1989-09-12 1992-09-08 Mitsubishi Jukogyo Kabushiki Kaisha Solid electrolyte fuel cell
US5053420A (en) 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
JPH052200A (ja) 1990-09-28 1993-01-08 Toshiba Corp 有機非線形光学材料
DE69318863T2 (de) 1992-02-03 1998-09-24 Fuji Photo Film Co Ltd Verfahren zur Dispergierung eines Farbstoffs und ein Farbstoff enthaltendes photographisches Silberhalogenidmaterial
JP2835246B2 (ja) 1992-06-02 1998-12-14 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
IL106877A (en) * 1992-09-10 1998-03-10 Lilly Co Eli Rhodanine derivatives for use as medicaments for the treatment of alzheimer's disease
DE69331891T2 (de) * 1992-09-11 2002-10-31 Agfa-Gevaert, Mortsel Photographisches Element,das einen Filterfarbstoff enthält, für Schnellverarbeitungs-Verwendungen
DE69333314D1 (de) * 1992-09-11 2004-01-08 Agfa Gevaert Nv Photographisches Element,das einen Filterfarbstoff enthält, für Schnellverarbeitungs-Verwendungen
JPH06128234A (ja) 1992-10-19 1994-05-10 Fuji Photo Film Co Ltd 不斉炭素原子を有する化合物およびそれからなる非線形光学材料
US5554767A (en) * 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
EP0687573A1 (en) * 1994-06-13 1995-12-20 Agfa-Gevaert N.V. Dye donor element for use in a thermal dye transfer method
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JPH08109176A (ja) 1994-10-07 1996-04-30 Torii Yakuhin Kk イソローダニンｎ酢酸誘導体
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US5618835A (en) * 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
JPH09255669A (ja) 1996-03-22 1997-09-30 Hisamitsu Pharmaceut Co Inc 新規なベンジリデン誘導体
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US6632947B2 (en) * 1997-02-18 2003-10-14 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
WO1999059586A1 (en) 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
AU6330999A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
US6221613B1 (en) * 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US6689491B1 (en) * 1999-02-08 2004-02-10 Fuji Photo Film Co., Ltd. Luminescent device material, luminescent device using the same, and amine compound
JP2001072592A (ja) * 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
EP1109808A1 (en) * 1999-07-01 2001-06-27 Geron Corporation Substituted indole compounds and their use for the treatment of cancer
US6720345B1 (en) * 1999-11-05 2004-04-13 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
US7005288B1 (en) * 1999-11-10 2006-02-28 Novozymes A/S Fungamyl-like alpha-amylase variants
JP2001348520A (ja) * 2000-04-03 2001-12-18 Fuji Photo Film Co Ltd メチン化合物、固体微粒子分散物、インクジェット用記録液、およびインクジェット記録方法
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
EP1299362A4 (en) 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
DE10115227A1 (de) * 2001-03-28 2002-12-19 Bayer Ag Optischer Datenträger enthaltend in der Informationsschicht eine lichtabsorbierende Verbindung mit mehreren chromophoren Zentren
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US7087758B2 (en) * 2001-04-06 2006-08-08 Smithkline Beecham Corporation Quinoline inhibitors of hyaki and hyak3 kinases
AR037714A1 (es) * 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
US20050019825A9 (en) * 2002-03-15 2005-01-27 Qing Dong Common ligand mimics: pseudothiohydantoins
US7482455B2 (en) * 2002-10-16 2009-01-27 Smithkline Beecham Corporation Chemical compounds
NZ539873A (en) * 2002-11-22 2008-09-26 Smithkline Beecham Corp Novel chemical compounds, thiazolidin-4-one, thiazol-4-one
US7645421B2 (en) * 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
EP1648452B1 (en) * 2003-07-28 2009-07-22 Merck Serono SA 2-imino-4-(thio)oxo-5-polycyclovinylazolines for use as pi3 kinase inhibitors
US20050042213A1 (en) * 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
US20090270456A1 (en) 2004-01-09 2009-10-29 Masaichi Hasegawa Novel chemical compounds
US20070117818A1 (en) 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
WO2005082363A1 (en) 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
US20070249599A1 (en) 2004-02-25 2007-10-25 Duffy Kevin J Novel Chemical Compounds
ATE420086T1 (de) * 2004-07-01 2009-01-15 Hoffmann La Roche Chinolinthiazolinone mit cdk-1 antiproliferativer wirkung
CA2571738A1 (en) * 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Thiazolinone unsubstituted quinolines
US7253285B2 (en) * 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
AR053602A1 (es) 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
US20090203692A1 (en) 2005-05-23 2009-08-13 Smithkline Beecham Corporation Novel chemical compounds
JP2008543769A (ja) 2005-06-08 2008-12-04 スミスクライン・ビーチャム・コーポレイション （５ｚ）−５−（６−キノキサリニルメチリデン）−２−［（２，４，６−トリクロロフェニル）アミノ］−１，３−チアゾール−４（５ｈ）−オン

Also Published As

Publication number Publication date
JP2008543770A (ja) 2008-12-04
EA200702457A1 (ru) 2008-04-28
IL187423A0 (en) 2008-02-09
KR20080014017A (ko) 2008-02-13
CN101193863A (zh) 2008-06-04
AU2006258032A1 (en) 2006-12-21
NO20080130L (no) 2008-01-08
ZA200709813B (en) 2008-09-25
BRPI0611096A2 (pt) 2010-12-21
EP1888531A4 (en) 2009-06-17
AR054059A1 (es) 2007-05-30
UY29581A1 (es) 2006-11-30
MA29567B1 (fr) 2008-06-02
US7674792B2 (en) 2010-03-09
MX2007015572A (es) 2008-02-25
TW200716580A (en) 2007-05-01
WO2006135712A2 (en) 2006-12-21
NZ563421A (en) 2010-07-30
EP1888531A2 (en) 2008-02-20
CA2611480A1 (en) 2006-12-21
AP2007004241A0 (en) 2007-12-31
US20070179144A1 (en) 2007-08-02
WO2006135712A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
EP1962827A4 (en) PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4-INHIBITORS WITH METFORMIN
AR057467A1 (es) Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
CR10832A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
EA200702568A1 (ru) Гетеробициклические ингибиторы металлопротеазы и их применение
CL2008003271A1 (es) Compuesto (2r)-2-[[(4-clorofenil)sulfonil][[2-fluoro-4-(1,2,4-oxadiazol-3-il)fenil]metil]amino]-5,5,5-trifluoropentanamida; composiciones farmaceuticas que lo contienen; y su uso en el tratamiento o retardo de la aparicion de la enfermedad de alzheimer, angiopatia amiloide cerebral, deterioro cognitivo leve y/o sindrome de down.
CL2007001090A1 (es) Compuestos derivados de diazepano, antagonistas de los receptores ccr-2, ccr-5 y ccr-3; procedimiento de preparacion; composicion farmaceutica; compuesto intermediario; y uso del compuesto en el tratamiento de una enfermedad oclusiva de arterias perifericas, isquemia critica de extremidades, angina inestable, apoplejia, entre otras
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
FR12C0031I1 (fr) Corps faconnes solides contenant des principes actifs, a usage externe, servant a lutter contre les parasites chez les animaux
PE20061373A1 (es) Composicion farmaceutica que contiene 'n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamida
NI201000047A (es) Uso de 3, 11b-cis-dihidrotetrabenzina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria.
UY31385A1 (es) Composicion farmacéutica de n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
BRPI0608176A2 (pt) usos de combinações, combinação e composição farmacêutica para o tratamento de cáncer
PE20070083A1 (es) (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
PE20071089A1 (es) Compuesto heterociclico fusionado como inhibidor de tirosina quinasa
IL188389A0 (en) Ethanolamine salt of n-(3-methoxy-5-methylpyrzin-2yl)-2-(4-[1,3,4-oxadiazole-2-yl]phenyl)
AR049078A1 (es) Forma cristalina de un compuesto de pirrolidina sustituida
CL2008002555A1 (es) Composicion farmaceutica que comprende un compuesto de levosimendan y un segundo ingrediente activo un antagonista del receptor de angiotensiva ii; un kit farmaceutico que comprende dicha composicion; y su uso para la prevencion o la inhibicion de apoplejia.
WO2007005787A3 (en) Methods and compositions for keratinocyte culture and therapeutics
AR052015A1 (es) Agente para la profilaxis o tratamiento del sindrome metabolico
SV2007002216A (es) Nueva combinacion antiparasitaria de principios activos ref. bhc041312-sv
WO2006133381A3 (en) (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,4,6-trichlorophenyl)amino]-1,3-thiazol-4(5h)-one
MX2022006127A (es) Polvo liofilizado que contiene 2-[(3-aminopropil)amino]etanotiol y su uso para preparar un termogel.
UY31062A1 (es) Combinaciones que comprenden pregabalina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed